The Cancer Therapeutic Drugs Market is expected to grow from US$238.4 billion in 2025 to US$361.0 billion in 2030, at a CAGR of 8.66%.
The cancer therapeutic drugs market is expected to grow at a fast pace during the forecast period due to the growing incidence of cancers worldwide. Geographically, North America is expected to hold the highest market share owing to the highest health spending of the United States among all the developed regions, in addition to having a high cancer prevalence in the country. The growing adoption of unhealthy living conditions is further driving the market growth during the forecast period.
Furthermore, growing cancer drug spending is driving the growth of the global cancer therapeutics market during the forecast period. The growing number of clinical trials has improved the chances of new innovations for targeted cancer treatment, driving market growth during the forecast period and beyond. Growing health awareness among people worldwide will lead to early diagnosis, further leading to the treatment of cancer, when detected at an early stage, thus, propelling the market growth in the forecast period.
Rising cancer incidences worldwide
Growing cancer drug spending
Increasing health awareness among people worldwide
The high cost of cancer treatment
On 17th June 2019, Pfizer announced that it has entered into a definitive merger agreement under which it will acquire Array Pharma.
On 31st August 2018, Servier Pharmaceuticals announced that it has completed the acquisition of Shire’s oncology business.
Major industry players profiled as part of the report are Pfizer Inc.[1], Celgene Corporation, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation, Janssen Global Services, LLC, Eli Lilly and Company, Merck & Co., Inc., and Astellas Pharma Inc.
| Report Metric | Details |
|---|---|
| Total Market Size in 2025 | USD 238.4 billion |
| Total Market Size in 2030 | USD 361.0 billion |
| Forecast Unit | Billion |
| Growth Rate | 8.66% |
| Study Period | 2020 to 2030 |
| Historical Data | 2020 to 2023 |
| Base Year | 2024 |
| Forecast Period | 2025 – 2030 |
| Segmentation | Indication, Product Type, Geography |
| Geographical Segmentation | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Companies |
|